Branches
Farrer Park
Mount Alvernia
Mount Alvernia – Surgical Oncology
Novena II
Orchard
Gleneagles
Icon Haematology Centre Mount Elizabeth
Mount Elizabeth
Novena I
Ongoing trials at ICON Cancer Centre
5 trials shown
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers li
- Study number:
- NCT05338970
- Cohorts:
- 2
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
- Study number:
- NCT05002127
- Cohorts:
- 1
- Study phase:
- 2, 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy, Chemotherapy
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC wi
- Study number:
- NCT04685135
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Chemotherapy, Biomarker
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-lin
- Study number:
- NCT04793958
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of respo
- Study number:
- NCT03888105
- Cohorts:
- 1
- Study phase:
- 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy